Pictet & Cie (Europe) Sa Arvinas, Inc. Transaction History
Pictet & Cie (Europe) Sa
- $4.53 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding ARVN
# of Institutions
224Shares Held
70.9MCall Options Held
1.52MPut Options Held
346K-
Vanguard Group Inc Valley Forge, PA7.06MShares$131 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$125 Million6.03% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.1MShares$76.1 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY3.33MShares$61.8 Million1.04% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $986M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...